文献速递心力衰竭与心肌病

慢性缺血性心力衰竭中克隆性造血:DNMT3A与TET2驱动基因突变克隆大小的预后作用

Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
PubMed 文献 · Eur Heart J · 2021-01-01

该研究对419例慢性缺血性心衰患者进行误差校正扩增子测序,通过时间依赖ROC曲线优化变异等位基因频率(VAF)阈值,发现TET2突变VAF≥0.73%、DNMT3A突变VAF≥1.15%与5年死亡率升高相关,双基因突变者死亡率最高。

要点

  • 56.2%患者携带DNMT3A或TET2突变(VAF>0.5%),其中59例双基因突变。
  • TET2突变VAF≥0.73%者5年死亡率32% vs <0.73%者19%(P=0.029)。
  • DNMT3A突变VAF≥1.15%者5年死亡率31% vs <1.15%者18%(P=0.048)。

核心结论

  • 本研究确定了DNMT3A和TET2驱动基因获得性体细胞突变所致克隆大小的新阈值,这些阈值与慢性缺血性心衰患者更差预后相关。

研究设计与样本

  • 对419例慢性缺血性心衰患者的骨髓和外周血来源细胞进行误差校正扩增子测序。
  • 通过时间依赖ROC曲线分析(基于删失数据)最大化敏感性与特异性,优化VAF截断值。

主要发现

  • 56.2%患者携带DNMT3A(N=173)或TET2(N=113)突变且VAF>0.5%,59例同时携带两种基因突变。
  • 无任何DNMT3A或TET2突变(VAF<0.5%)者5年死亡率为18%。
  • 仅携带一种DNMT3A或TET2驱动突变且VAF高于相应截断值者5年死亡率为29%。
  • 同时携带DNMT3A和TET2驱动突变且VAF均高于相应截断值者5年死亡率为42%。
  • DNMT3A突变VAF≥1.15%者5年死亡率为31%,VAF<1.15%者为18%(P=0.048);TET2突变VAF≥0.73%者5年死亡率为32%,VAF<0.73%者为19%(P=0.029)。

关键数值与推荐

  • TET2克隆性造血驱动突变的优化VAF截断值为0.73%。
  • DNMT3A克隆性造血驱动突变的优化VAF截断值为1.15%。

临床怎么用

  • 在慢性缺血性心衰患者中,可考虑检测DNMT3A和TET2体细胞突变及其VAF克隆大小以辅助风险分层。
  • VAF高于上述阈值的DNMT3A或TET2突变携带者,尤其是双基因突变者,可能属于预后更差的高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Somatic mutations of the epigenetic regulators DNMT3A and TET2 causing clonal expansion of haematopoietic cells (clonal haematopoiesis; CH) were shown to be associated with poor prognosis in chronic ischaemic heart failure (CHF). The aim of our analysis was to define a threshold of variant allele frequency (VAF) for the prognostic significance of CH in CHF. METHODS AND RESULTS: We analysed bone marrow and peripheral blood-derived cells from 419 patients with CHF by error-corrected amplicon sequencing. Cut-off VAFs were optimized by maximizing sensitivity plus specificity from a time-dependent receiver operating characteristic (ROC) curve analysis from censored data. 56.2% of patients were carriers of a DNMT3A- (N = 173) or a TET2- (N = 113) mutation with a VAF >0.5%, with 59 patients harbouring mutations in both genes. Survival ROC analyses revealed an optimized cut-off value of 0.73% for TET2- and 1.15% for DNMT3A-CH-driver mutations. Five-year-mortality was 18% in patients without any detected DNMT3A- or TET2 mutation (VAF < 0.5%), 29% with only one DNMT3A- or TET2-CH-driver mutations above the respective cut-off level and 42% in patients harbouring both DNMT3A- and TET2-CH-driver mutations above the respective cut-off levels. In carriers of a DNMT3A mutation with VAF ≥ 1.15%, 5-year mortality was 31%, compared with 18% mortality in those with VAF < 1.15% (P = 0.048). Likewise, in patients with TET2 mutations, 5-year mortality was 32% with VAF ≥ 0.73%, compared with 19% mortality with VAF < 0.73% (P = 0.029). CONCLUSION: The present study defines novel threshold levels for clone size caused by acquired somatic mutations in the CH-driver genes DNMT3A and TET2 that are associated with worse outcome in patients with CHF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Assmus B, Cremer S, Kirschbaum K, et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J. 2021. PMID: 33241418. doi:10.1093/eurheartj/ehaa845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。